2004
DOI: 10.1124/jpet.103.060814
|View full text |Cite
|
Sign up to set email alerts
|

NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-Benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: A New Selective Inhibitor of T-Type Calcium Channels

Abstract: Mibefradil is a Ca 2ϩ channel antagonist that inhibits both Ttype and high-voltage-activated Ca 2ϩ channels. We previously showed that block of high-voltage-activated channels by mibefradil occurs through the production of an active metabolite by intracellular hydrolysis. In the present study, we modified the structure of mibefradil to develop a nonhydrolyzable analog, (1S, 2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate d… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
157
2

Year Published

2004
2004
2022
2022

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 157 publications
(164 citation statements)
references
References 19 publications
5
157
2
Order By: Relevance
“…However, in contrast, the recent investigation reported that mibefradil also blocked the L-type Ca 2+ channel by active metabolite produced via intracellular hydrolysis. Therefore, non-hydrolyzable analogue of mibefradil, NNC 55-0396, was developed as a selective blocker of the T-type Ca 2+ channel (Huang et al, 2004). We showed that cumulative addition of mibefradil and NNC 55-0396 produced concentration-dependent inhibition of frequency as well as amplitude of spontaneous Ca 2+ transients and contractions, respectively.…”
Section: Discussionmentioning
confidence: 99%
“…However, in contrast, the recent investigation reported that mibefradil also blocked the L-type Ca 2+ channel by active metabolite produced via intracellular hydrolysis. Therefore, non-hydrolyzable analogue of mibefradil, NNC 55-0396, was developed as a selective blocker of the T-type Ca 2+ channel (Huang et al, 2004). We showed that cumulative addition of mibefradil and NNC 55-0396 produced concentration-dependent inhibition of frequency as well as amplitude of spontaneous Ca 2+ transients and contractions, respectively.…”
Section: Discussionmentioning
confidence: 99%
“…First, we applied NNC 55-0396, a nonhydrolyzable analog of mibefradil, which is more specific for T-type channels because it lacks the effects of the mibefradil metabolite on HVA Ca 2ϩ channels (Huang et al, 2004); 50 M NNC 55-0396 applied for Ͼ15 min inhibited LVA Ca 2ϩ influx (Fig. 4C 1 ), reduced the amplitude of the somatic APs (Fig.…”
Section: Resultsmentioning
confidence: 99%
“…42). Notably, the reduction in cell proliferation in response to either mibefradil or TTL1177 was accompanied by a significant increase in activation of caspase-3/7 ( Fig.…”
Section: Inhibition Of T-type Ca 2þ Channels Induces P53-dependent Apmentioning
confidence: 99%